Brainstorm Cell Therapeutics Inc., of New York, said it will not make Nurown available under the newly enacted Right to Try Act, at this time but will continue to focus efforts on completing the ongoing phase III study with the product as quickly as possible with the goal of bringing a treatment option to amyotrophic lateral sclerosis patients.